Skip to main content

Animations

MJFF Publications

6851 - 6860 of 8785 Results
Title
Year
  • Year
  • 2018
  • 2021
  • 2024
  • 2022
  • 2013
  • 2019
  • 2021
  • 2025
  • 2021
  • 2023
  • Summary Details
    OPEN
    Title: Myosin VI-Dependent Actin Cages Encapsulate Parkin-Positive Damaged Mitochondria
    Journal Name: Developmental Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.devcel.2018.01.007
    Citation Count: 101
  • Summary Details
    OPEN
    Title: Mutation in protein disulfide isomerase A3 causes neurodevelopmental defects by disturbing endoplasmic reticulum proteostasis
    Journal Name: The EMBO Journal
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.15252/embj.2020105531
    Citation Count: 23
  • Summary Details
    RESTRICTED
    Title: Evaluation of Protein Identification and Quantification by the diaPASEF Method on timsTOF SCP
    Journal Name: Journal of the American Society for Mass Spectrometry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1021/jasms.4c00067
    Citation Count: 3
  • Summary Details
    OPEN
    Title: A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells11061018
    Citation Count: 5
  • Summary Details
    RESTRICTED
    Title: TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2013.06.005
    Citation Count: 39
  • Summary Details
    OPEN
    Title: The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss
    Journal Name: Experimental Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.expneurol.2019.05.002
    Citation Count: 12
  • Summary Details
    OPEN
    Title: An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of α-synuclein
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.celrep.2021.109189
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson’s disease
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-025-00896-z
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Tackling underrepresentation to aid understanding of Parkinson’s disease: Progress and further opportunities
    Journal Name: Physiology News
    Publisher: The Physiological Society
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.36866/123.32
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Intra-arterial bone marrow mononuclear cells for stroke
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00005-4
    Citation Count: 1
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.